ATEX Stock Analysis: Anterix | NASDAQ
Telecom Services | NASDAQ, USA | Market Cap: 1.856m USD | 12M Return: 295.9% | US03676C1009 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 30.3M
Qual. Beats: 0
Rev. Trend: 88.2%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Anterix Inc. (NASDAQ: ATEX) is a wireless communications company that commercializes spectrum assets to support private broadband networks for utilities and other critical infrastructure operators. The company monetizes its 900 MHz spectrum holdings-covering the contiguous United States, Hawaii, Alaska, and Puerto Rico-primarily by leasing spectrum rights that allow customers to deploy their own dedicated LTE networks instead of relying on commercial carrier services.
The companys product portfolio includes the CatalyX ecosystem platform, complementary spectrum offerings, the Anterix Security Collective, and rural broadband services. The 900 MHz band is particularly well-suited for utility-grade private networks because lower-frequency signals propagate over long distances and through dense vegetation or structures, enabling wide-area coverage with fewer cell sites.
Anterix was incorporated in 1997 and is headquartered in Woodland Park, New Jersey. The company previously operated as pdvWireless before adopting its current name in August 2019, and it trades as a small-cap stock within the Communication Services sector under the Wireless Telecommunication Services sub-industry.
- Major utility customers sign 900 MHz private LTE contracts
- FCC 900 MHz band clearing completion unlocks spectrum monetization timeline
- Negative operating cash flow intensifies capital structure and dilution risk
| Net Income: 65.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 13.95 > 1.0 |
| NWC/Revenue: 1.73k% < 20% (prev 327.7%; Δ 1.40k% < -1%) |
| CFO/TA 0.02 > 3% & CFO 10.7m > Net Income 65.7m |
| Net Debt (-107.5m) to EBITDA (1.96m): -54.74 < 3 |
| Current Ratio: 4.85 > 1.5 & < 3 |
| Outstanding Shares: last quarter (19.6m) vs 12m ago 4.94% < -2% |
| Gross Margin: 93.41% > 18% (prev 100.0%; Δ -6.59% > 0.5%) |
| Asset Turnover: 1.64% > 50% (prev 1.65%; Δ -0.01% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.24 (Total Current Assets 153.1m - Total Current Liabilities 31.5m) / Total Assets 497.9m |
| B: -0.61 (Retained Earnings -302.1m / Total Assets 497.9m) |
| C: 0.00 (EBIT TTM 1.52m / Avg Total Assets 428.8m) |
| D: 1.35 (Book Value of Equity 285.8m / Total Liabilities 212.1m) |
| Altman-Z'' = 1.06 = BB |
| DSRI: 2.25 (Receivables 14.3m/5.33m, Revenue 7.04m/5.92m) |
| GMI: 1.07 (GM 100.0% / 93.41%) |
| AQI: 0.82 (AQ_t 0.68 / AQ_t-1 0.83) |
| SGI: 1.19 (Revenue 7.04m / 5.92m) |
| TATA: 0.11 (NI 65.7m - CFO 10.7m) / TA 497.9m) |
| Beneish M = -1.89 (Cap -4..+1) = B |
As of August 30, 2026, the stock is trading at USD 92.33 with a total of 200,797 shares traded. Over the past week, the price has changed by -0.99%, over one month by +1.05%, over three months by +41.96% and over the past year by +295.93%.
Current recommended Stop Loss: 81.80 (which is 11.4% or 1.6 ATR below the current price).
Anterix has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy ATEX.
- StrongBuy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 112.3 | 21.7% |
P/E Trailing = 27.1261
P/S = 263.664
P/B = 6.445
Revenue TTM = 7.04m USD
EBIT TTM = 1.52m USD
EBITDA TTM = 1.96m USD
Long Term Debt = 2.64m USD (estimated: total debt 4.09m - short term 1.45m)
Short Term Debt = 1.45m USD (from shortTermDebt, last quarter)
Debt = 8.51m USD (from shortLongTermDebtTotal, last quarter) + Leases 4.42m
Net Debt = -107.5m USD (calculated: Debt 8.51m - CCE 116.0m)
Enterprise Value = 1.75b USD (1.86b + Debt 8.51m - CCE 116.0m)
Interest Coverage Ratio = unknown (Ebit TTM 1.52m / Interest Expense TTM 0.0)
EV/FCF = 119.8x (Enterprise Value 1.75b / FCF TTM 14.6m)
FCF Yield = 0.83% (FCF TTM 14.6m / Enterprise Value 1.75b)
FCF Margin = 207.3% (FCF TTM 14.6m / Revenue TTM 7.04m)
Net Margin = 933.0% (Net Income TTM 65.7m / Revenue TTM 7.04m)
Gross Margin = 93.41% ((Revenue TTM 7.04m - Cost of Revenue TTM 464k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 3.51 (Enterprise Value 1.75b / Total Assets 497.9m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 8.51m)
Taxrate = 10.49% (7.70m / 73.4m)
NOPAT = 1.36m (EBIT 1.52m * (1 - 10.49%))
Current Ratio = 4.85 (Total Current Assets 153.1m / Total Current Liabilities 31.5m)
Debt / Equity = 0.03 (Debt 8.51m / totalStockholderEquity, last quarter 285.8m)
Debt / EBITDA = -54.74 (Net Debt -107.5m / EBITDA 1.96m)
Debt / FCF = -7.37 (Net Debt -107.5m / FCF TTM 14.6m)
Total Stockholder Equity = 256.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 15.32% (Net Income 65.7m / Total Assets 497.9m)
RoE = 25.65% (Net Income TTM 65.7m / Total Stockholder Equity 256.1m)
RoCE = 0.59% (EBIT 1.52m / Capital Employed (Equity 256.1m + L.T.Debt 2.64m))
RoIC = 0.29% (NOPAT 1.36m / Invested Capital 467.5m)
WACC = 10.11% (E(1.86b)/V(1.86b) * Re(10.16%) + D(8.51m)/V(1.86b) * Rd(0.0%) * (1-Tc(0.10)))
Discount Rate = 10.16% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 74.04 | Cagr: 2.71%
[DCF] Terminal Value 69.51% ; FCFF base≈14.6m ; Y1≈14.7m ; Y5≈15.5m
[DCF] Fair Price = 14.95 (EV 185.7m - Net Debt -107.5m = Equity 293.2m / Shares 19.6m; r=10.11% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.02 | # QB: 0
Revenue Correlation: 88.16 | Revenue CAGR: 30.07% | SUE: -0.10 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.04 | Chg30d=-120.17% | Revisions=+40% | Analysts=3
EPS next Quarter (2026-12-31): EPS=-0.21 | Chg30d=-213.00% | Revisions=+40% | Analysts=3
EPS current Year (2027-03-31): EPS=-1.11 | Chg30d=+28.60% | Revisions=+0% | GrowthEPS=-123.1% | GrowthRev=+220.4%
EPS next Year (2028-03-31): EPS=-0.59 | Chg30d=-113.09% | Revisions=+0% | GrowthEPS=+47.0% | GrowthRev=-14.4%
[Analyst] Revisions Ratio: +57% (up=4, down=0)